Research
Hormonal
Tirzepatide reduced incident obstructive sleep apnea (OSA) compared with liraglutide (0.89; 0.82–0.97) but not semaglutide (0.94; 0.86–1.02).
Tirzepatide may be beneficial in managing both diabetes and associated sleep apnea in patients.
StrongSupportsmedium confidence
Moreover, tirzepatide reduced incident OSA compared with liraglutide (0.89; 0.82–0.97) but not semaglutide (0.94; 0.86–1.02).
Why this rating
Based on a retrospective cohort analysis in a large global database.
Source
Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence
Alex E. Henney et al. · Annals of the American Thoracic Society · 2025
cohort · n=15668Cited 12×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →